2010-01-12 - Bioglan at BioSquare Geneva 2010
The main objective of taking part of BioSquare is to establish new collaborations within our contract development and manufacturing organisation. Bioglan has also marketing authorisation of mainly traditional dermatological products for the Scandinavian market. We are open for in-licensing opportunities with focus on topical products for the Scandinavian market.
The main objective for taking part of BioSquare is to make our contract development and manufacturing organisation available to other organisations, which require this type of service. We offer all services you require within the field of semi-solids and liquids.
New products are continuously developed within the Reig Jofré Group and we also look for partners for these products all over the world. Two products registered as medical device are within short offered for out-licensing.
- The product, presently called Zalve, is designed to facilitate healing and prevent the growth of microorganisms in small wounds. This product can be used as a first aid cream and is an alternative treatment to topical antibiotics.
- The product, presently called Ameliorin, is a microemulsion which prevents and alleviates perennial rhinitis allergy where symptoms are caused by pollen, dust mite, animal fur and other allergens by forming a protective barrier in the nasal cavity.
Please contact us for a meeting on the official home page of BioSquare: www.biosquare.com